RECENT NEWS

A new Biothreats Radar capable of scanning biological risks that pose a threat to the public will be key to the UK’s fight and preparation for future pandemics, the Government has announced. It’s part of a new Biological Security Strategy to defend the UK from infectious disease outbreaks, antimicrobial resistance, and biological incidents and attacks.

Scientists from across the UK are hoping to learn how they can better predict leukaemia occurrence, as well as develop improved drug screening pathways to treat the disease, through a major funding boost worth £12 million.

BIOHIT HealthCare will be launching its GastroPanel Quick Test at BSG LIVE’23, which will take place from 19-22 June at the Arena and Conference Centre (ACC) Liverpool. This annual meeting provides the ideal opportunity to share this innovation with colleagues in the gastroenterology and hepatology community, as they come together to discuss the latest advances in the field.

GrapheneDx, General Graphene Corporation and Sapphiros have announced a strategic partnership to industrialise graphene-based biosensors for medical devices used to diagnose a variety of diseases at the point of care and in consumer settings.

Revvity has announced the launch of its Signals Research Suite, a unified, cloud-native software-as-a-service (SaaS) platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.

Roche has announced that the HPV test for use on the cobas 6800/8800 systems has been awarded World Health Organization (WHO) prequalification. WHO prequalification expands the availability of this critical HPV screening tool in countries that rely on the global organisation’s list in making purchasing and implementation decisions.

Axol Bioscience, a leading pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialise its extensive collection of Alzheimer’s disease (AD) patient samples.

Thermo Fisher Scientific has launched its new Thermo Scientific Orbitrap Astral mass spectrometer, which it says is one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyser combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever.

Serious Hazards of Transfusion (SHOT) has announced details of two new webinars to focus on patient identification for safe transfusion.

The European Laboratory Research & Innovation Group (ELRIG) UK has announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool on 18–19 October. Professor Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this year’s event focusing on diverse thinking and new perspectives.

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

Beckman Coulter Life Science has boosted the field of microbioreactor research with the launch of its powerful new Light Array Module (LAM) for the popular BioLector XT Microbioreactor. This new advancement now enables work with light-dependent organisms that need to perform photosynthesis to grow.

Digital pathology and clinical AI firm Paige has announced a new AI-based digital assay to support pathologists in the detection and diagnosis of microsatellite instability (MSI) status in colon cancers.

Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics have announced a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice.

A new tool which could help reduce the spread of antimicrobial resistance is showing early promise, through exploiting a bacterial immune system as a gene editing tool, according to new research.

Revvity has announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis.

CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), has announced that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).

Cellular Origins has launched Constellation, its closed, configurable, robotic platform at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting 2023. Designed to automate the manufacturing of advanced therapies without significant process redevelopment, Constellation combines aseptic fluid handling technologies with advanced automation.

Avacta, a life sciences company developing targeted oncology drugs and diagnostics, has acquired Belgian firm Coris Bioconcept which develops, manufactures and markets rapid diagnostic test kits.

New research has revealed further details of how Alzheimer’s disease is caused, and a blood test could predict who will go on to develop the condition. A new paper published in Nature Medicine by staff at the University of Pittsburgh School of Medicine found that the build-up of amyloid protein in the brain, long associated with the disease, may in itself not be enough to cause symptoms.